Tevimbra (tislelizumab-jsgr) — Medica

Initial criteria

• age ≥ 18 years
• ONE of the following: (i) BOTH of: EITHER liver-confined unresectable disease ineligible for transplant OR extrahepatic/metastatic disease ineligible for resection, transplant, or locoregional therapy AND used first-line; OR (ii) used for subsequent therapy
• prescribed by or in consultation with an oncologist

Approval duration

1 year